[Prognostic aspects in the treatment of chronic heart insufficiency].
Treatment of patients with heart failure due to major ventricular systolic dysfunction should aim not only at symptomatic but also at prognostic improvement. If correction of the underlying problem is not possible, treatment should slow down the progression of cardiac failure and eliminate triggers for sudden cardiac death due to electromechanical dissociation or arrhythmias. In every patient with chronic congestive heart failure screening for myocardial ischemia and complete revascularization is mandatory, if possible. In patients with coronary artery disease and diminished systolic function, beta-blockade may improve prognosis by reducing ischemic events and sudden cardiac death. The incidence of life-threatening arrhythmias in patients with heart failure may be reduced by eliminating facilitating factors like electrolyte disturbances, altered autonomic tone and raised intracardiac pressure rather than by antiarrhythmic medical treatment itself. One of the most important prognostic aspects in treatment is the interference with the development of the cardiomyopathy of overload, uniformly observed in chronic congestive heart failure. Modification of mechanical and neuroendocrine stimuli may postpone myocardial hypertrophy and interstitial hyperplasia as a consequence of altered gene expression. Early treatment with ACE inhibitors and in certain patients with betablockers are the most promising strategies to delay the progression of the disease. In contrast, positive inotropic drugs, including digitalis and phosphodiesterase inhibitors, do not improve prognosis. Calcium antagonists should also be used with restriction, as Verapamil and Diltiazem, but also Nifedipine may adversely affect the outcome in congestive heart failure patients.
Bertel
O
O
Kardiologische Abteilung, Stadtspital Triemli, Zürich.
D001145:Arrhythmias, Cardiac / Q000150:complications / Q000628:therapy; D009202:Cardiomyopathies / Q000150:complications / Q000628:therapy; D002317:Cardiovascular Agents / Q000627:therapeutic use*; D003327:Coronary Disease / Q000150:complications / Q000628:therapy; D006333:Heart Failure / Q000175:diagnosis / Q000628:therapy*; D006801:Humans; D009204:Myocardial Revascularization; D011379:Prognosis
D002317:Cardiovascular Agents
Prognostische Aspekte in der Behandlung der chronischen Herzinsuffizienz.